SOURCE: Given Imaging

Given Imaging

November 02, 2009 16:01 ET

Given Imaging to Host November 23rd Meeting and Webcast to Discuss New Features of PillCam® COLON2 and Review Results From Israeli Feasibility Trial

YOQNEAM, ISRAEL--(Marketwire - November 2, 2009) - Given Imaging Ltd. (NASDAQ: GIVN), the global leader in capsule endoscopy, today announced that it will host a meeting with members of the financial community to discuss new features of the company's second-generation PillCam® COLON and review results from the recently completed Israeli feasibility study. The meeting will take place on Monday, November 23rd at the Novotel London ExCel Hotel, Western Gateway, Royal Victoria Dock, E16 1AA, London, UK. The meeting will begin at 2:00pm London Time, 9:00am New York Time, and 4pm Israel Time.

Speakers will include:

--  Homi Shamir, President and CEO of Given Imaging
--  Prof. Rami Eliakim, Rambam Medical Center and Prof. Sam Adler, Bikkur
    Holim Hospital, principal investigators from the PillCam COLON2 feasibility
    trial who will review results
--  Prof. Jacques Devière, Erasme Hospital, Brussels will discuss the need
    for alternatives to colonoscopy in Europe
    

If interested in attending the meeting in person, please call +212-867-1768 or email dcarey@lazarpartners.com. To participate in the teleconference, please dial one of the following numbers ten minutes before the conference is scheduled to begin:

--  U.S. participants: 1-888-219-1217
--  U.K. participants: 08081017548
--  All other international callers please dial +913-312-1463 and include
    appropriate codes for dialing the U.S.
    

This meeting will also be webcast live at www.givenimaging.com. A replay of the call will be available for two weeks on the company's website, or until December 7, 2009 by dialing 888-203-1112. Callers outside of the U.S. should dial 719-457-0820. The replay participant code is 8784603.

About PillCam COLON

PillCam COLON enables the physician to directly see the colon mucosa in its natural state while not requiring sedation, intubation, air insufflation, hospitalization or radiation. PillCam COLON is a smooth plastic capsule which can be naturally ingested with a sip of water. It utilizes advanced optical technology with tiny video cameras at each end, which produces enhanced resolution images and includes automatic light control and a wide field of view.

About Given Imaging Ltd.

Given Imaging has advanced gastrointestinal diagnosis by developing innovative, patient-friendly tools based on its PillCam® Platform. PillCam capsule endoscopy provides physicians with natural images of the small intestine via PillCam® SB, the esophagus through PillCam® ESO, and the colon with PillCam® COLON [PillCam COLON is not cleared for use in the USA]. The PillCam capsules are miniature video cameras that patients ingest. Given Imaging's other capsule products include Agile™ patency capsule, to verify intestinal patency, and Bravo®, the only wireless, catheter-free, 48-hour pH test commercially available for pH testing to assess gastroesophageal reflux disease (GERD). Given Imaging's products use cutting-edge, wireless technology and advanced software to enable gastroenterologists to evaluate and detect abnormalities of the esophagus, small bowel and colon and more accurately treat patients. All Given Imaging products allow patients to maintain normal activities. Since 2001, more than one million PillCam® video capsules have helped physicians evaluate patients for GI disorders. Given Imaging's headquarters, manufacturing and R&D facilities are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia and Singapore. For more information, please visit http://www.givenimaging.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (3) our success in implementing our sales, marketing and manufacturing plans, (4) protection and validity of patents and other intellectual property rights, (5) the impact of currency exchange rates, (6) the effect of competition by other companies, (7) the outcome of significant litigation, (8) our ability to obtain reimbursement for our product from government and commercial payors, (9) quarterly variations in operating results, (10) the possibility of armed conflict or civil or military unrest in Israel, (11) the impact of global economic conditions, and (12) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2008. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Contact Information